News

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...
Stocktwits on MSN18d
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved their Dupixent injection for the treatment of adult patients ...
Healio4h
Outcomes for asthma with allergic bronchopulmonary aspergillosis improve with dupilumab
Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...
GlobalData on MSN13d
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
BioPharma Dive1d
Apogee touts positive data for atopic dermatitis drug
The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...
pharmaphorum1d
Sanofi sheds Regeneron stake, but insists collaboration is unaffected
French drugmaker Sanofi plans to sell off most of its 20.6% stake in US biotech Regeneron, but says it remains committed to the longstanding alliance ...
Wall Street Journal18d
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ - The Wall Street Journal
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...
pharmaphorum1d
Apogee rises as long-acting eczema drug heads for phase 3
Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...
Living Well With COPD: New Campaign Provides Critical Support And Resources To Families Across The Country Facing Common Lung Disease
The Lung Association's Living Well with COPD campaign provides free one-on-one COPD support, education and resources tailored for every stage of the disease. The campaign is created for all families ...
Healio7d
Q&A: Mepolizumab marks second biologic approved for COPD with eosinophilic phenotype
The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...
BioSpace13d
Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...
PMLive15d
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous pemphigoid (BP) in adults. The drug is now the only targeted medicine ...